CN1602888A - Azithromycin enteric casing preparation and its preparing process - Google Patents
Azithromycin enteric casing preparation and its preparing process Download PDFInfo
- Publication number
- CN1602888A CN1602888A CN 200410071762 CN200410071762A CN1602888A CN 1602888 A CN1602888 A CN 1602888A CN 200410071762 CN200410071762 CN 200410071762 CN 200410071762 A CN200410071762 A CN 200410071762A CN 1602888 A CN1602888 A CN 1602888A
- Authority
- CN
- China
- Prior art keywords
- azithromycin
- enteric
- preparation
- granule
- pvp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses an azitromvcin granule-containing eneric-coated preparation and its preparing method, where the composition of an azitromvcin granule in weight shares: azitromvcin 115-135, lactose 0-60, microcrystalline cellulose 50-150, low-substituted hydroxypropyl cellulose 5-15, cross-linked PVP 5-15, and PVPk30 a proper amount, and it can be tablet, capsule and granule in form. It can be quickly released in intestine, thus increasing drug absorbing speed.
Description
Technical field
The present invention relates to a kind of Azithromycin enteric casing preparation and preparation method thereof, specifically, relate to enteric coated preparation of the azithromycin granule that contains specific adjuvant composition and preparation method thereof.
Background technology
Azithromycin is novel macrolide antibiotic, has unique pharmacokinetic characteristics and broad-spectrum antibacterial activity, its chemistry (2R by name, 3S, 4R, 5R, 8R, 10R, 11R, 12S, 13S, 14R)-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-nuclear-own pyrans glycosyl) oxygen]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-seven methyl isophthalic acid 1-[[3,4,6-three deoxidations-3-(dimethylamino)-β-D-wood-own pyrans glycosyl] oxygen]-1-oxa--6-azacyclo-pentadecane-15 ketone.Azithromycin is by suppressing the synthetic antibacterial action that reaches of ribosome 50s protein subunit matter in the bacterial cell, has broad spectrum antibiotic activity, except having the antimicrobial spectrum of erythromycin, can suppress multiple aerobic and anaerobism gram-positive cocci, mycoplasma, chlamydia is outside the legionella pneumophilia, the more important thing is that it can also suppress the escherichia coli etc. of some aerobic and anaerobism gram negative bacteria, especially hemophilus influenzas and Enterobacter; Can be distributed in the many organs and tissues of whole body rapidly behind the azithromycin oral, make tissue concentration be higher than 10～100 times of serum-concentrations, and sustainable several days, azithromycin can also be absorbed rapidly by phagocyte simultaneously, be carried into infection site, make infection site concentration higher, have unique pharmacokinetic characteristics and broad-spectrum antibacterial activity, be mainly used in treatment: the acute pharyngitis that micrococcus scarlatinae causes, acute tonsillitis; The sinusitis that sensitive bacterial causes, otitis media, acute bronchitis, acute episode of chronic bronchitis; Pneumonia due to streptococcus pneumoniae, hemophilus influenza and the mycoplasma pneumoniae; Urethritis and cervicitis due to chlamydia trachomatis and the non-multiple drug resistance Diplococcus gonorrhoeae; The skin soft-tissue infection that sensitive bacterial causes.Azithromycin is at present domestic and international clinical quite valued broad spectrum antibiotic.
Recent research shows azithromycin degraded 68% in 30 minutes in the 0.1mol/L hydrochloric acid solution, and this shows that azithromycin is unstable in gastric juice.And azithromycin belongs to macrolide antibiotics, the side reaction that this class medicine ubiquity GI irritation, discomfort such as cause that the patient vomits easily.
Though reported some enteric coated preparation in the prior art about azithromycin, as: CN1223116 A discloses Azithromycin enteric tablet and the enteric coated micropill that contains starch, low-substituted hydroxypropyl cellulose; CN 1149831 A disclose enteric-coated slow releasing tablet; CN 1285192 A disclose use enteric material parcel azithromycin granule.But disclosed Azithromycin enteric casing preparation has usually and has that intravital bioavailability is lower, onset slow, the pharmaceutical adjunct consumption is big in that find to use at present and the prior art, taking dose greatly problem.At present still need a kind of new enteric coated preparation that azithromycin is discharged rapidly at enteral, improve the infiltration rate of medicine, the quickening medicine improves bioavailability to patient's onset time.
Therefore, a kind of absorption of further quickening azithromycin, the enteric coated preparation of raising bioavailability have been the purpose of this invention is to provide.
Summary of the invention
The present invention to achieve these goals, combination to the adjuvant of the enteric coated preparation that contains azithromycin is studied, discovery can improve the rate of release of pharmaceutical dosage form in intestinal juice significantly by the enteric coated preparation of mainly being made up of the azithromycin granule that contains the specific composition proportioning, improves bioavailability.
Therefore in order to achieve the above object, the invention provides a kind of Azithromycin enteric casing preparation, described enteric coated preparation is selected from enteric coated tablet, enteric coated capsule, enteric coated particles, mainly form, it is characterized in that the composition weight proportion of azithromycin granule is: azithromycin 115-135 part, lactose 0-60 part, microcrystalline Cellulose 50-150 part, low-substituted hydroxypropyl cellulose 5-15 part, cross-linked pvp 5-15 part, PVP by azithromycin granule
K30In right amount.Find relatively that by experiment the granule that adds a small amount of lactose in granule still can keep particulate character, contains the formed enteric coated preparation of the granule that is not higher than 60 parts of lactose and still have higher rate of release in intestinal juice.
One of ordinary skill in the art are under the prerequisite of the releasing effect that guarantees preparation, in order to reduce the content of adjuvant in the pharmaceutical preparation, preferably in compositions, do not add lactose (being that lactose is 0 part), so the composition weight proportion of the azithromycin granule in the preferred enteric coated preparation of the present invention is: azithromycin 115-135 part, microcrystalline Cellulose 50-150 part, low-substituted hydroxypropyl cellulose 5-15 part, cross-linked pvp 5-15 part, PVP
K30In right amount.
Preferably, the composition weight proportion of azithromycin granule is: azithromycin 115-135 part, microcrystalline Cellulose 65-135 part, low-substituted hydroxypropyl cellulose 6.5-13.5 part, cross-linked pvp 6.5-13.5 part, PVP
K30In right amount;
Better, the composition weight proportion of azithromycin granule is: azithromycin 115-135 part, microcrystalline Cellulose 80-120 part, low-substituted hydroxypropyl cellulose 8.0-12.0 part, cross-linked pvp 8.0-12.0 part, PVP
K30In right amount;
Most preferably, the composition weight proportion of azithromycin granule is: azithromycin 120-130 part, microcrystalline Cellulose 95-105 part, low-substituted hydroxypropyl cellulose 9.5-10.5 part, cross-linked pvp 9.5-10.5 part, PVP
K30In right amount.
On the other hand, the present invention has provided that the concrete composition weight proportion of azithromycin granule is in the enteric coated preparation: 125 parts of azithromycins, 100 parts of microcrystalline Cellulose, 10 parts of low-substituted hydroxypropyl celluloses, 10 parts of cross-linked pvps, PVP
K30In right amount.
Be applied to the enteric coated tablet that enteric coated preparation of the present invention can wrap up enteric coating for the label that is formed by the azithromycin granule compacting, enteric coating weightening finish preferably accounts for 12% of label weight, and enteric coating can be selected Opadry-93018359 for use.Preferably before compressed cores, tabletting behind azithromycin granule and the 1 part of sodium lauryl sulphate mix homogeneously.
The present invention provides a kind of method for preparing Azithromycin enteric casing preparation on the other hand, and its preparation technology may further comprise the steps:
(1) takes by weighing azithromycin, lactose, microcrystalline Cellulose, low-substituted hydroxypropyl cellulose, the cross-linked pvp of recipe quantity, cross 80-100 mesh sieve, mixing respectively;
(2) make soft material in right amount with the 5%PVP aqueous solution after, cross 24-40 mesh sieve (preferred mistake 24 mesh sieves) and make granule;
(3) put granule in 40-60 ℃, aeration-drying 2-4 hour;
(4) cross 24-40 mesh sieve granulate, promptly get azithromycin granule;
(5) azithromycin granule is further made Azithromycin enteric casing preparation.
(5) concrete step is for getting the azithromycin granule that step (4) makes, tabletting, obtain label (preferably before tabletting, in azithromycin granule, add 1 part of sodium lauryl sulphate, mixing), get label, weigh rearmounted coating pan inner control temperature to 30-50 ℃, coating solution is sprayed into coating pan coating (weightening finish of preferred coating be label 12%) continuously, and drying makes the Azithromycin enteric sheet.Coating solution can be selected Opadry-03018359 aqueous solution for use.
Those skilled in the art can expect that according to general knowledge the granule that will contain specific proportioning composition among the present invention is applied to other enteric coated preparation and can reaches effect preferably equally, as capsule or granule.It may occur to persons skilled in the art that contain the particulate enteric coated capsule of the present invention and enteric coated granule still can remain in the intestinal juice infiltration rate that discharges, improve medicine rapidly, accelerate medicine to onset time of patient, improve the effect of bioavailability.Therefore the present invention provides on the other hand:
(1) enteric coated capsule of forming by enteric capsule shell and fill azithromycin granule therein.One of ordinary skill in the art can adopt following method preparation: with the azithromycin granule that step (4) makes, sieve, the enteric coated capsule of packing into makes Azithromycin enteric capsule.
(2) enteric coated particles of forming by the enteric coating of azithromycin granule and enwrapped granule.One of ordinary skill in the art can adopt following method preparation: with the azithromycin granule that step (4) makes, sieve, adopt and dip in wet method, dip in wetly with coating solution, after the drying, reuse coating solution dips in wet, drying, repeatable operation 4-8 time makes the Azithromycin enteric granule.
Description of drawings
Fig. 1 represents that the label release that different auxiliary material composition preparation of granules goes out compares
Fig. 2 represents to contain the release of the particulate enteric coatel tablets of invention under various influence conditions relatively
The specific embodiment
Embodiment 1: particulate preparation
Prescription:
Azithromycin 12.5g
Microcrystalline Cellulose 10g
Cross-linked pvp 1g
Low-substituted hydroxypropyl cellulose 1g
5%PVP
K30Aqueous solution is an amount of
Preparation technology:
To cross 100 mesh sieves through the qualified azithromycin of full inspection.Microcrystalline cellulose excipients, low-substituted hydroxypropyl cellulose, cross-linked pvp are crossed 100 mesh sieves, PVP respectively
K30Water is made 5% aqueous solution.Take by weighing azithromycin, microcrystalline Cellulose, low-substituted hydroxypropyl cellulose, the cross-linked pvp mixing of recipe quantity, make soft material with the 5%PVP aqueous solution after, 24 mesh sieve system granules.Granule was put in 60 ℃ of drying baker aeration-drying after 2 hours, 24 mesh sieve granulate.
The comparative example 1:
Prescription:
Azithromycin 12.5g
Microcrystalline Cellulose 10g
Carboxymethyl starch sodium 0.5g
5%PVP
K30Aqueous solution is an amount of
Preparation technology: take by weighing the supplementary material of each comparative example's recipe quantity, prepare granule with the preparation technology of embodiment 1.
The comparative example 2:
Prescription:
Azithromycin 12.5g
Microcrystalline Cellulose 10g
Carboxymethyl starch sodium 1g
5%PVP
K30Aqueous solution is an amount of
Preparation technology: take by weighing the supplementary material of each comparative example's recipe quantity, prepare granule with the preparation technology of embodiment 1.
The comparative example 3:
Prescription:
Azithromycin 12.5g
Microcrystalline Cellulose 10g
Cross-linked pvp 1g
5%PVP
K30Aqueous solution is an amount of
Preparation technology: take by weighing the supplementary material of each comparative example's recipe quantity, prepare granule with the preparation technology of embodiment 1.
Embodiment 2: the release of label in intestinal juice of different prescriptions
4 kinds of respectively that embodiment 1 and comparative example 1-3 is prepared granules add the sodium lauryl sulphate of 0.1g, mixing, tabletting.Tablet hardness is controlled at 4～6kg/mm
2Relatively the foregoing description 1 and the prepared release of label in intestinal juice (phosphate buffer pH6.8) of comparative example find that the label among the embodiment 1 can discharge active medicine at short notice in a large number in intestinal juice, the results are shown in Table 1.
Table 1 label release in intestinal juice is investigated
| Embodiment 1 | The comparative example 1 | The comparative example 2 | The comparative example 3 | |
| Release (%) | 95 | 65 | 72 | 85 |
Conclusion: particulate label and the comparative example of being contained embodiment 1 by The above results as can be seen compare, azithromycin has very high rate of release in intestinal juice, this has guaranteed that the label outer coatings is dissolved in intestinal juice after, the azithromycin in the label discharges rapidly, improves bioavailability.
Embodiment 3: contain particulate enteric coated tablet
Get that particulate label carries out enteric coating among the above-mentioned embodiment of containing 1:
Preparation technology: take by weighing 180g Opadry-93018359, be scattered in the 1000ml water, shake up, promptly get coating solution.Get label, in the rearmounted coating pan of weighing, coating, weightening finish 12%.
The Azithromycin enteric sheet smooth surface rounding that makes is measured its release in gastric juice and intestinal juice, the results are shown in Table 2
Table 2 Azithromycin enteric sheet release is investigated
| ?1 | ?2 | ?3 | ?4 | ?5 | ?6 | Meansigma methods | |
| Stripping quantity in the gastric juice (%) | ?1.2 | ?1.8 | ?2.9 | ?2.4 | ?3.4 | ?2.7 | ?2.4 |
| Release in the intestinal juice (%) | ?99.1 | ?93.3 | ?98.0 | ?97.7 | ?98.2 | ?93.9 | ?96.7 |
Conclusion: by The above results as can be seen, in intestinal juice, discharge rapidly at short notice, have releasing effect preferably by the prepared enteric coated tablet of granule among the embodiment 1.
Embodiment 4: high temperature, high humidity, high light influence the release of enteric coated tablet
Get embodiment 3 prepared enteric coated tablets and investigate the release influence of high temperature, high humidity, high light under the following conditions enteric coated tablet.Get the enteric coatel tablets sample respectively and be tiled in right amount in the culture dish, under each condition, placed 10 days, in the 5th, 10 day, the difference sampling and measuring, measurement result sees Table 3.
(1) hot test: place 60 ℃ calorstat;
(2) high wet test: under the condition of 25 ℃ of relative humidity RH90 ± 5%, place;
(3) strong illumination test: place the illumination under 4500Lx ± 500Lx of light cupboard;
The release of table 3 Azithromycin enteric sheet under different condition investigated
| Condition | Burst size in the gastric juice in the stripping quantity intestinal juice |
| 5 | 2.4％??????????96.7％ 2.7％??????????95.9％ 2.6％??????????95.1％ 2.8％??????????96.1％ 2.9％??????????94.8％ 2.5％??????????95.4％ 2.3％??????????95.9％ |
Conclusion: above-mentioned experimental result shows, but still retention properties is stable under the various harsh conditions of high temperature, high humidity and high light by the prepared enteric coated tablet of the granule of embodiment 1, discharges characteristics rapidly.
Embodiment 5:
Enteric coated tablet prescription composition and preparation technology by embodiment 3 carry out scale-up, manufacture experimently 3 batches, and its release is investigated.The results are shown in Table 4, table 5.
Three batches of trial-productions of amplifying sample of table 4 Azithromycin enteric sheet
| Lot number | Production scale | The raw material input amount | Compressed cores quantity | Output behind the coating | Yield |
| 1 | 10000 | 1340g | 9611 | 9611 | 96.1％ |
| 2 | 10000 | 1340g | 9574 | 9574 | 95.7％ |
| 3 | 10000 | 1340g | 9645 | 9645 | 96.4％ |
Three batches of release conditions of amplifying sample of table 5 Azithromycin enteric sheet
| Lot number | Stripping quantity in the gastric juice | Release in the intestinal juice |
| 1 | 2.5％ | 96.4％ |
| 2 | 2.7％ | 95.3％ |
| 3 | 2.3％ | 95.9％ |
Conclusion: by the prepared enteric coated tablet favorable reproducibility on commercial production of the granule of embodiment 1, same process can make the satisfactory finished product of release.
Claims (20)
1. Azithromycin enteric casing preparation, described enteric coated preparation is selected from enteric coated tablet, enteric coated capsule, enteric coated particles, enteric coated preparation mainly is made up of azithromycin granule, it is characterized in that the composition weight proportion of azithromycin granule is: azithromycin 115-135 part, lactose 0-60 part, microcrystalline Cellulose 50-150 part, low-substituted hydroxypropyl cellulose 5-15 part, cross-linked pvp 5-15 part, PVP
K30In right amount.
2. Azithromycin enteric casing preparation as claimed in claim 1, the composition weight proportion of wherein said azithromycin granule is: azithromycin 115-135 part, microcrystalline Cellulose 50-150 part, low-substituted hydroxypropyl cellulose 5-15 part, cross-linked pvp 5-15 part, PVP
K30In right amount.
3. Azithromycin enteric casing preparation as claimed in claim 2, the composition weight proportion of wherein said azithromycin granule is: azithromycin 115-135 part, microcrystalline Cellulose 65-135 part, low-substituted hydroxypropyl cellulose 6.5-13.5 part, cross-linked pvp 6.5-13.5 part, PVP
K30In right amount.
4. Azithromycin enteric casing preparation as claimed in claim 3, the composition weight proportion of wherein said azithromycin granule is: azithromycin 115-135 part, microcrystalline Cellulose 80-120 part, low-substituted hydroxypropyl cellulose 8.0-12.0 part, cross-linked pvp 8.0-12.0 part, PVP
K30In right amount.
5 Azithromycin enteric casing preparations as claimed in claim 4, the composition weight proportion of wherein said azithromycin granule is: azithromycin 120-130 part, microcrystalline Cellulose 95-105 part, low-substituted hydroxypropyl cellulose 9.5-10.5 part, cross-linked pvp 9.5-10.5 part, PVP
K30In right amount.
6. Azithromycin enteric casing preparation as claimed in claim 5, the composition weight proportion of wherein said azithromycin granule is: 125 parts of azithromycins, 100 parts of microcrystalline Cellulose, 10 parts of low-substituted hydroxypropyl celluloses, 10 parts of cross-linked pvps, PVP
K30In right amount.
7. as any one Azithromycin enteric casing preparation as described in the claim 1-6, wherein said enteric coated preparation is the enteric coated tablet that label is wrapped with enteric coating, and described label is pressed into by azithromycin granule.
8. Azithromycin enteric casing preparation as claimed in claim 7, wherein azithromycin granule is before compressed cores, with tabletting behind 1 part of sodium lauryl sulphate mix homogeneously.
9. Azithromycin enteric casing preparation as claimed in claim 7, wherein said enteric coating weightening finish accounts for 12% of label weight.
10. Azithromycin enteric casing preparation as claimed in claim 9, wherein said enteric coating are Opadry-93,018 359.
11. as any one Azithromycin enteric casing preparation as described in the claim 1-6, wherein said enteric coated preparation is an enteric coated capsule, this enteric coated capsule is made up of enteric capsule shell and fill azithromycin granule therein.
12. as any one Azithromycin enteric casing preparation as described in the claim 1-6, wherein said enteric coated preparation is an enteric coated particles, this enteric coated particles is made up of the enteric coating of azithromycin granule and enwrapped granule.
13. the preparation method of any Zitromax enteric coated preparation of claim 1-6, its preparation technology may further comprise the steps:
(1) takes by weighing azithromycin, lactose, microcrystalline Cellulose, low-substituted hydroxypropyl cellulose, the cross-linked pvp of recipe quantity, cross 80-100 mesh sieve, mixing respectively;
(2) make soft material in right amount with the 5%PVP aqueous solution after, cross the 24-40 mesh sieve and make granule;
(3) put granule in 40-60 ℃, aeration-drying 2-4 hour;
(4) cross 24-40 mesh sieve granulate, promptly get azithromycin granule;
(5) azithromycin granule that obtains in the step (4) is further made Azithromycin enteric casing preparation.
Make granule 14. cross 24 mesh sieves in the preparation method as claimed in claim 13, wherein said step (2).
15. as claim 13 or 14 described preparation methoies, the process that wherein said step (5) further makes Azithromycin enteric casing preparation is:
Get the azithromycin granule that step (4) makes, tabletting obtains label, gets label, and the rearmounted coating pan inner control temperature of weighing sprays into the coating pan coating to 30-50 ℃ continuously with coating solution, and drying makes the Azithromycin enteric sheet.
16., wherein in azithromycin granule, add 1 part of sodium lauryl sulphate, mixing before the tabletting as claim 15 described preparation methoies.
17. as claim 15 described preparation methoies, the weightening finish of wherein said coating is 12% of a label.
18. as claim 17 described preparation methoies, wherein said coating solution is the aqueous solution that contains Opadry-03018359.
19. as claim 13 or 14 described preparation methoies, the process that wherein said step (5) further makes Azithromycin enteric casing preparation is:
Get the azithromycin granule that step (4) makes, sieve, adopt and to dip in wet method, dip in wetly with coating solution, after the drying, reuse coating solution dips in wet, drying, and repeatable operation 4-8 time makes the Azithromycin enteric granule.
20. as claim 13 or 14 described preparation methoies, the process that wherein said step (5) further makes Azithromycin enteric casing preparation is:
Get the azithromycin granule that step (4) makes, sieve, the enteric coated capsule of packing into makes Azithromycin enteric capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410071762 CN1284540C (en) | 2004-07-30 | 2004-07-30 | Azithromycin enteric casing preparation and its preparing process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410071762 CN1284540C (en) | 2004-07-30 | 2004-07-30 | Azithromycin enteric casing preparation and its preparing process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1602888A true CN1602888A (en) | 2005-04-06 |
| CN1284540C CN1284540C (en) | 2006-11-15 |
Family
ID=34666825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410071762 Active CN1284540C (en) | 2004-07-30 | 2004-07-30 | Azithromycin enteric casing preparation and its preparing process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1284540C (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006067576A1 (en) * | 2004-12-21 | 2006-06-29 | Pfizer Products Inc. | Enteric coated azithromycin multiparticulates |
| CN100382805C (en) * | 2006-01-11 | 2008-04-23 | 南京工业大学 | Azithromycin enteric casing microsphere and its preparing process |
| CN101390848B (en) * | 2008-11-12 | 2010-04-21 | 浙江丽水众益药业有限公司 | Medicine composition azithromycin enteric-coated capsules |
| CN103156814A (en) * | 2011-12-09 | 2013-06-19 | 四川科伦药物研究有限公司 | Azithromycin enteric composition and preparation method |
| CN107582538A (en) * | 2017-06-01 | 2018-01-16 | 合肥远志医药科技开发有限公司 | Azithromycin capsule and preparation method thereof |
| CN113116859A (en) * | 2021-04-12 | 2021-07-16 | 海南普利制药股份有限公司 | Azithromycin pill core coating preparation |
-
2004
- 2004-07-30 CN CN 200410071762 patent/CN1284540C/en active Active
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006067576A1 (en) * | 2004-12-21 | 2006-06-29 | Pfizer Products Inc. | Enteric coated azithromycin multiparticulates |
| CN100382805C (en) * | 2006-01-11 | 2008-04-23 | 南京工业大学 | Azithromycin enteric casing microsphere and its preparing process |
| CN101390848B (en) * | 2008-11-12 | 2010-04-21 | 浙江丽水众益药业有限公司 | Medicine composition azithromycin enteric-coated capsules |
| CN103156814A (en) * | 2011-12-09 | 2013-06-19 | 四川科伦药物研究有限公司 | Azithromycin enteric composition and preparation method |
| CN103156814B (en) * | 2011-12-09 | 2015-11-25 | 四川科伦药物研究有限公司 | A kind of Azithromycin enteric composition and preparation method |
| CN107582538A (en) * | 2017-06-01 | 2018-01-16 | 合肥远志医药科技开发有限公司 | Azithromycin capsule and preparation method thereof |
| CN113116859A (en) * | 2021-04-12 | 2021-07-16 | 海南普利制药股份有限公司 | Azithromycin pill core coating preparation |
| CN113116859B (en) * | 2021-04-12 | 2022-08-30 | 海南普利制药股份有限公司 | Azithromycin pill core coating preparation |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1284540C (en) | 2006-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2222309B1 (en) | Antibiotic macrocycle compounds and methods of manufacture and use thereof | |
| CN1244869A (en) | Crystal form O of clarithromycin | |
| CN105125524B (en) | Tilmicosin enteric-coated micro-pill and preparation method thereof | |
| CN1284540C (en) | Azithromycin enteric casing preparation and its preparing process | |
| CN106176646B (en) | Tosufloxacin tosylate dispersible tablets and preparation method thereof | |
| CN1843505A (en) | Compound Doxycycline lysozyme enteral capsule | |
| CN101002747A (en) | Slow release preparation of cefaclor | |
| CN105919960B (en) | A kind of roxithromycin dispersing tablet and preparation method thereof | |
| CN103145733A (en) | Amoxicillin compound and pharmaceutical composition of amoxicillin compound and potassium clavulanate | |
| CN101002745A (en) | Slow release preparation of cefdinir | |
| CN1257715C (en) | Clindamycin metronidazole vagina effervescent tablet and its preparing method and use | |
| CN113116859B (en) | Azithromycin pill core coating preparation | |
| CN106176613B (en) | One kind sustained release erythromycin thiocyanate soluble powder for animals and preparation method thereof | |
| CN112569196B (en) | Clindamycin phosphate vaginal tablet and preparation process thereof | |
| CN1319533C (en) | Cefetamet pivoxil hydrochloride dispersion dispersion tablets and preparation method | |
| CN1593448A (en) | Kelarmycin dry suspensoid and its preparing process | |
| CN101011363A (en) | Slow release tablet of amoxicillin | |
| CN103070839A (en) | Sitafloxacin tablet and preparation method thereof | |
| CN1813722A (en) | Composition containing amoxicillin and dicloxacillin sodium | |
| CN101579327A (en) | Azithromycin enteric capsule and preparation method thereof | |
| CN103040787A (en) | Azithromycin capsule and preparation method thereof | |
| CN1813783A (en) | Azithromycin micro-pill capsule and its preparing method | |
| CN1589807A (en) | Erythromycin micro pill enteric coatel tablet and its preparation method | |
| CN1223116A (en) | Enteric soluble azithromycin preparation | |
| CN1236814C (en) | Faluopeinan medicine composition containing glutathione |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |